carteolol has been researched along with Diabetic Glomerulosclerosis in 1 studies
Carteolol: A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In order to determine the appropriate dosage of carteolol in renal dysfunction, the pharmacokinetics of carteolol has been examined in appropriate patients." | 1.28 | Pharmacokinetics of carteolol in patients with impaired renal function. ( Amemiya, M; Asano, Y; Furuya, H; Sakairi, Y; Tabei, K, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amemiya, M | 1 |
| Tabei, K | 1 |
| Furuya, H | 1 |
| Sakairi, Y | 1 |
| Asano, Y | 1 |
1 other study available for carteolol and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Pharmacokinetics of carteolol in patients with impaired renal function.
Topics: Adult; Aged; Carteolol; Chronic Disease; Creatinine; Diabetic Nephropathies; Female; Glomerulonephri | 1992 |